Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 201–300 of 1,000
Song, H., Sun, X., Zhang, L., Zhao, L., Guo, Z.-M., Fan, H., Zhong, A., Niu, W., Dai, Y., Zhang, L.-Y., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.03.008 · Cited by 103
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Antolín, A. A., Workman, P., Mestres, J., & Al‐Lazikani, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923115828 · Cited by 111
Wang, T., Liu, X.-H., Guan, J., Ge, S., Wu, M.-B., Lin, J.-P., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 93
Rapid traversal of vast chemical space using machine learning-guided docking screens
Luttens, A., de Vaca, I. C., Sparring, L., Brea, J. M., Martínez, A. L., Kahlous, N. A., Radchenko, D. S., Moroz, Y. S., Loza, M. I., Norinder, U., et al. (2025) · Nature Computational Science · doi:10.1038/s43588-025-00777-x · Cited by 117
Rothman, R. B., Baumann, M. H., Prisinzano, T. E., & Newman, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.007 · Cited by 107
A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
Brown, E. S., Park, J., Marx, C. E., Hynan, L. S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., Lo, A., & Holmes, T. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.138 · Cited by 96
“Pregnenolone may act through multiple mechanisms (Roth et al, 2004; Zorumski et al, 2013b), including microtubules *Correspondence: Dr ES Brown, Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, MC 8849, Dallas, TX 75390-8849, USA, Tel: +214…”
BackgroundTinnitus: network pathophysiology-network pharmacology
Elgoyhen, A. B., Langguth, B., Vanneste, S., & De Ridder, D. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00001 · Cited by 96
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone
Im, D., Inoue, A., Fujiwara, T., Nakane, T., Yamanaka, Y., Uemura, T., Mori, C., Shiimura, Y., Kimura, K., Asada, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20221-0 · Cited by 96
Molecular basis for selective activation of DREADD-based chemogenetics
Zhang, S., Gumpper, R. H., Huang, X., Liu, Y., Krumm, B. E., Cao, C., Fay, J. F., & Roth, B. L. (2022) · Nature · doi:10.1038/s41586-022-05489-0 · Cited by 97
Self-citationNeurogenic Actions of Atypical Antipsychotic Drugs and Therapeutic Implications
Newton, S. S., & Duman, R. S. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00002 · Cited by 100
Discovery of new GPCR ligands to illuminate new biology
Roth, B. L., Irwin, J. J., & Shoichet, B. K. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2490 · Cited by 94
Self-citationŠtrac, D. Š., Pivac, N., Smolders, I. J., Fogel, W. A., Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00492 · Cited by 106
“Selective” serotonin 5-HT2A receptor antagonists
Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 96
Fukuda, T., Hashimoto, H., Okayasu, N., Kameyama, A., Onogi, H., Nakagawasai, O., Nakazawa, T., Kurosawa, T., Hao, Y., Isaji, T., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172536 · Cited by 98
Schreiber, R., & Newman‐Tancredi, A. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.015 · Cited by 97
Designing transient binding drugs: A new concept for drug discovery
Ohlson, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.001 · Cited by 93
Abbott, C., Jaramillo, A. A., Wilcox, C. E., & Hamilton, D. A. (2013) · Current Medicinal Chemistry · doi:10.2174/092986713804870864 · Cited by 103
Martino, D., Karnik, V., Osland, S., Barnes, T. R. E., & Pringsheim, T. M. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718777392 · Cited by 92
Improving Current Treatments for Schizophrenia
Marić, N. P., Jovicic, M. J., Mihaljevic, M. M., & Miljević, Č. (2016) · Drug Development Research · doi:10.1002/ddr.21337 · Cited by 95
Quinoline- and Isoquinoline-Sulfonamide Analogs of Aripiprazole: Novel Antipsychotic Agents?
Zajdel, P., Partyka, A., Marciniec, K., Bojarski, A. J., Pawłowski, M., & Wesołowska, A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.158 · Cited by 95
Roth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.654764 · Cited by 88
Self-citationMultifunctional drugs with different CNS targets for neuropsychiatric disorders
Van der Schyf, C. J., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04141.x · Cited by 88
Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 90
Self-citationCan we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 87
Interactions of antioxidants isolated from tart cherry (Prunus cerasus) fruits
Kirakosyan, A., Seymour, E., Noon, K. R., Urcuyo-Llanes, D. E., Kaufman, P. B., Warber, S. L., & Bolling, S. F. (2010) · Food Chemistry · doi:10.1016/j.foodchem.2010.02.017 · Cited by 95
Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids
Coa, J. C., Castrillón-L, W., Cardona, W., Cardá, M., Ospina, V., Muñoz, J. A., Vélez, I. D., & Robledo, S. M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.018 · Cited by 87
Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
Leeson, P. D., & Empfield, J. R. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45024-1 · Cited by 85
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 92
Latapy, C., Rioux, V., Guitton, M. J., & Beaulieu, J.-M. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0094 · Cited by 82
Boeckler, F. M., & Gmeiner, P. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.007 · Cited by 92
Serotonin 2A receptor antagonists for treatment of schizophrenia
Ebdrup, B. H., Rasmussen, H., Arnt, J., & Glenthøj, B. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601738 · Cited by 82
Understanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 87
The glycine transport inhibitor sarcosine is an NMDA receptor co‐agonist that differs from glycine
Zhang, H. X., Hyrc, K. L., & Thio, L. L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.168757 · Cited by 82
Yadav, P. N., Kroeze, W. K., Farrell, M. S., & Roth, B. L. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183780 · Cited by 82
Self-citationDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders
Lee, H.-M., & Kim, Y. (2016) · Schizophrenia Research and Treatment · doi:10.1155/2016/6378137 · Cited by 80
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 82
Abbas, A., & Roth, B. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802532707 · Cited by 78
Self-citationArmbruster, B. N., & Roth, B. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r400030200 · Cited by 80
Self-citationPharmacogenomics: A road ahead for precision medicine in psychiatry
Pardiñas, A. F., Owen, M. J., & Walters, J. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.011 · Cited by 90
Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 84
Drug repurposing for cancer therapy, easier said than done
González‐Fierro, A., & Dueñas‐González, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.012 · Cited by 85
Nikolic, K. M., Mavridis, L., Djikić, T., Vučićević, J., Agbaba, D. D., Yelekçi, K., & Mitchell, J. B. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00265 · Cited by 83
In silico prediction of chemical mechanism of action via an improved network‐based inference method
Wu, Z., Lü, W., Wu, D., Luo, A., Bian, H., Li, J., Li, W., Liu, G., Huang, J. Y., Cheng, F., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13629 · Cited by 85
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 82
Barceló, M., Raviña, E., Masaguer, C. F., Domínguez, E., Areias, F. M., Brea, J. M., & Loza, M. I. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.045 · Cited by 78
Hahn, M., Chintoh, A. F., Giacca, A., Xu, L., Lam, L., Mann, S. W., Fletcher, P. J., Guenette, M. D., Cohn, T. A., Wolever, T., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.004 · Cited by 84
The Recognition of Identical Ligands by Unrelated Proteins
Barelier, S., Sterling, T., O’Meara, M. J., & Shoichet, B. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00683 · Cited by 74
Next-generation drug repurposing using human genetics and network biology
Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 75
Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat
Jassim, G., Skrede, S., Vázquez, M. J., Wergedal, H., Vik-Mo, A. O., Lunder, N., Diéguez, C., Vidal-Puig, A., Berge, R. K., López, M., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2397-y · Cited by 74
Classics in Chemical Neuroscience: Haloperidol
Tyler, M. W., Zaldívar-Díez, J., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00018 · Cited by 81
Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist
Yin, W., Zhou, X. E., Yang, D., de Waal, P. W., Wang, M., Dai, A., Cai, X., Huang, C., Liu, P., Wang, X., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0009-2 · Cited by 81
Conciliating binding efficiency and polypharmacology
Mestres, J., & Gregori‐Puigjané, E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.004 · Cited by 78
Neurosteroids: mechanistic considerations and clinical prospects
Maguire, J. L., & Mennerick, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01626-z · Cited by 78
Wang, K., Sun, J., Zhou, S., Wan, C., Qin, S., Li, C., He, L., & Yang, L. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003315 · Cited by 78
Huber, T., Menon, S., & Sakmar, T. P. (2008) · Biochemistry · doi:10.1021/bi800891r · Cited by 76
Chen, Z., Fan, L., Wang, H., Yu, J., Lu, D., Qi, J., Nie, F., Luo, Z., Liu, Z., Cheng, J., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00971-w · Cited by 78
A pathophysiological paradigm for the therapy of psychiatric disease
Spedding, M., Jay, T. M., Silva, J. C. E., & Perret, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1753 · Cited by 78
Lin, X., Huang, X.-P., Chen, G., Whaley, R., Peng, S., Wang, Y., Zhang, G., Wang, S. X., Wang, S., Roth, B. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300338m · Cited by 73
Self-citationDíaz‐Holguín, A., Saarinen, M., Vo, D. D., Sturchio, A., Branzell, N., de Vaca, I. C., Hu, H., Mitjavila-Domènech, N., Lindqvist, A., Baranczewski, P., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn1524 · Cited by 80
Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.
Potvin, S., Zhornitsky, S., & Stip, É. (2015) · Europe PMC (PubMed Central) · Cited by 84
Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs
Beaulieu, J.-M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006857 · Cited by 71
Facing the Challenges of Structure-Based Target Prediction by Inverse Virtual Screening
Schomburg, K. T., Bietz, S., Briem, H., Henzler, A. M., Urbaczek, S., & Rarey, M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500130e · Cited by 78
Yun, S., Yang, B., Anair, J. D., Martin, M. M., Fleps, S. W., Pamukcu, A., Yeh, N.-H., Contractor, A., Kennedy, A., & Parker, J. G. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01390-9 · Cited by 73
Physiogenomic association of statin‐related myalgia to serotonin receptors
Ruaño, G., Thompson, P. D., Windemuth, A., Seip, R. L., Dande, A., Sorokin, A., Kocherla, M., Smith, A., Holford, T. R., & Wu, A. H. B. (2007) · Muscle & Nerve · doi:10.1002/mus.20871 · Cited by 69
Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
Rampino, A., Marakhovskaia, A., Soares-Silva, T., Torretta, S., Veneziani, F., & Beaulieu, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00702 · Cited by 80
Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs
Roth, B. L. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0252-8 · Cited by 75
Self-citationZamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
Fenfluramine: a plethora of mechanisms?
Sourbron, J., & Lagae, L. G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1192022 · Cited by 70
Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders
Monteleone, P., Martiadis, V., & Maj, M. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.08.003 · Cited by 80
Antiplasmodial activity of novel keto-enamine chalcone-chloroquine based hybrid pharmacophores
Sashidhara, K. V., Kumar, M., Modukuri, R. K., Srivastava, R. K., Soni, A., Srivastava, K., Singh, S. V., Saxena, J. K., Gauniyal, H. M., & Puri, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.011 · Cited by 70
Schmid, C. L., Streicher, J. M., Meltzer, H. Y., & Bohn, L. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.38 · Cited by 79
Ren, Y., Li, S., Zhu, R., Wan, C., Song, D., Zhu, J., Cai, G., Long, S., Kong, L., & Yu, W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00136 · Cited by 69
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 76
Prefrontal afferents to the dorsal raphe nucleus in the rat
Gonçalves, L., Nogueira, M. I., Shammah‐Lagnado, S. J., & Metzger, M. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.11.012 · Cited by 78
Medicinal chemistry strategies in follow-on drug discovery
Zhao, H., & Guo, Z. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.008 · Cited by 73
Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01184.x · Cited by 68
Roth, B. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.012 · Cited by 73
Self-citationStructure, dynamics and lipid interactions of serotonin receptors: excitements and challenges
Sarkar, P., Mozumder, S., Bej, A., Mukherjee, S., Sengupta, J., & Chattopadhyay, A. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00772-8 · Cited by 71
Screening the receptorome: an efficient approach for drug discovery and target validation
Strachan, R. T., Ferrara, G., & Roth, B. L. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.012 · Cited by 74
Self-citationSetola, V., Dukat, M., Glennon, R. A., & Roth, B. L. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009266 · Cited by 71
Self-citationYohn, S. E., & Conn, P. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.012 · Cited by 69
Traditional Herbal Medicines Against CNS Disorders from Bangladesh
Uddin, M. J., & Zidorn, C. (2020) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00269-7 · Cited by 75
Van der Schyf, C. J., Gal, S., Geldenhuys, W. J., & Youdim, M. B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.873 · Cited by 66
Perspectives on cognitive domains, H3receptor ligands and neurological disease
Hancock, A. A., & Fox, G. B. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.10.1237 · Cited by 66
Zhornitsky, S., Rizkallah, É., Pampoulova, T., Chiasson, J., Stip, É., Rompré, P.-P., & Potvin, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e7810a · Cited by 77
Drug Effect Prediction by Polypharmacology-Based Interaction Profiling
Simon, Z., Peragovics, Á., Vigh-Smeller, M., Csukly, G., Tombor, L., Yang, Z., Zahoránszky-Köhalmi, G., Végner, L., Jelinek, B., Hári, P., et al. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2002022 · Cited by 68
Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa
Verhagen, L. A. W., Luijendijk, M. C. M., Hillebrand, J. J., & Adan, R. A. H. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.09.005 · Cited by 69
Vollenweider, F. X., Barro, M., Csomor, P., & Feldon, J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.058 · Cited by 70
The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Yadav, P. N., Abbas, A. I., Farrell, M. S., Setola, V., Sciaky, N., Huang, X., Kroeze, W. K., Crawford, L. K., Piel, D., Keiser, M. J., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.195 · Cited by 66
Self-citationGrygier, P., Pustelny, K., Nowak, J., Golik, P., Popowicz, G. M., Plettenburg, O., Dubin, G., Menezes, F., & Czarna, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01887 · Cited by 66
Neves, G. A., Menegatti, R., Antonio, C. B., Grazziotin, L. R., Vieira, R. O., Rates, S. M. K., Noël, F., Barreiro, E. J., & Fraga, C. A. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.040 · Cited by 64
Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities
Schaffhauser, H., Mathiasen, J. R., DiCamillo, A., Huffman, M. J., Lu, L. D., McKenna, B. A., Qian, J., & Marino, M. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.021 · Cited by 68
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
“Antipsychotic drugs are known to bind to a variety of dopaminergic, serotoninergic, alpha-adrenergic, histaminergic and muscarinic receptors [1].”
BackgroundQuetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair
Zhornitsky, S., Yong, V. W., Koch, M. W., Mackie, A., Potvin, S., Patten, S. B., & Metz, L. M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12154 · Cited by 64
Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain
McOmish, C. E., Lira, A., Hanks, J. B., & Gingrich, J. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.139 · Cited by 69
Structure‐Based Virtual Screening for Dopamine D 2 Receptor Ligands as Potential Antipsychotics
Kaczor, A. A., Silva, A., Loza, M. I., Kolb, P., Castro, M., & Poso, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500599 · Cited by 63
Investigation of the Relationship between Topology and Selectivity for Druglike Molecules
Yang, Y., Chen, H., Nilsson, I., Mureşan, S., & Engkvist, O. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1008456 · Cited by 63
Weston, M., Kaserer, T., Wu, A. J., Mouravlev, A., Carpenter, J. C., Snowball, A., Knauß, S., von Schimmelmann, M. J., During, M. J., Lignani, G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw1567 · Cited by 67
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.